154 related articles for article (PubMed ID: 23590517)
1. Microfluidic chemical cytometry of peptide degradation in single drug-treated acute myeloid leukemia cells.
Kovarik ML; Shah PK; Armistead PM; Allbritton NL
Anal Chem; 2013 May; 85(10):4991-7. PubMed ID: 23590517
[TBL] [Abstract][Full Text] [Related]
2. Response of single leukemic cells to peptidase inhibitor therapy across time and dose using a microfluidic device.
Kovarik ML; Dickinson AJ; Roy P; Poonnen RA; Fine JP; Allbritton NL
Integr Biol (Camb); 2014 Feb; 6(2):164-74. PubMed ID: 24413844
[TBL] [Abstract][Full Text] [Related]
3. Dielectrophoretic Microfluidic Chip Enables Single-Cell Measurements for Multidrug Resistance in Heterogeneous Acute Myeloid Leukemia Patient Samples.
Khamenehfar A; Gandhi MK; Chen Y; Hogge DE; Li PC
Anal Chem; 2016 Jun; 88(11):5680-8. PubMed ID: 27149245
[TBL] [Abstract][Full Text] [Related]
4. Aminopeptidase inhibition by the novel agent CHR-2797 (tosedostat) for the therapy of acute myeloid leukemia.
Jenkins C; Hewamana S; Krige D; Pepper C; Burnett A
Leuk Res; 2011 May; 35(5):677-81. PubMed ID: 21145592
[TBL] [Abstract][Full Text] [Related]
5. Targeting acute myeloid leukemia with a proapoptotic peptide conjugated to a Toll-like receptor 2-mediated cell-penetrating peptide.
Li K; Lv XX; Hua F; Lin H; Sun W; Cao WB; Fu XM; Xie J; Yu JJ; Li Z; Liu H; Han MZ; Hu ZW
Int J Cancer; 2014 Feb; 134(3):692-702. PubMed ID: 23852533
[TBL] [Abstract][Full Text] [Related]
6. Mimicking the Acute Myeloid Leukemia Niche for Molecular Study and Drug Screening.
Houshmand M; Soleimani M; Atashi A; Saglio G; Abdollahi M; Nikougoftar Zarif M
Tissue Eng Part C Methods; 2017 Feb; 23(2):72-85. PubMed ID: 28007011
[TBL] [Abstract][Full Text] [Related]
7. p70S6 kinase is a target of the novel proteasome inhibitor 3,3'-diamino-4'-methoxyflavone during apoptosis in human myeloid tumor cells.
Piedfer M; Bouchet S; Tang R; Billard C; Dauzonne D; Bauvois B
Biochim Biophys Acta; 2013 Jun; 1833(6):1316-28. PubMed ID: 23481040
[TBL] [Abstract][Full Text] [Related]
8. Isolation of specific and biologically active peptides that bind cells from patients with acute myeloid leukemia (AML).
Galili N; Devemy E; Raza A
J Hematol Oncol; 2008 Jul; 1():8. PubMed ID: 18616802
[TBL] [Abstract][Full Text] [Related]
9. Lanthanide-doped nanoparticles conjugated with an anti-CD33 antibody and a p53-activating peptide for acute myeloid leukemia therapy.
Niu F; Yan J; Ma B; Li S; Shao Y; He P; Zhang W; He W; Ma PX; Lu W
Biomaterials; 2018 Jun; 167():132-142. PubMed ID: 29571049
[TBL] [Abstract][Full Text] [Related]
10. Protein targeting chimeric molecules specific for dual bromodomain 4 (BRD4) and Polo-like kinase 1 (PLK1) proteins in acute myeloid leukemia cells.
Mu X; Bai L; Xu Y; Wang J; Lu H
Biochem Biophys Res Commun; 2020 Jan; 521(4):833-839. PubMed ID: 31708096
[TBL] [Abstract][Full Text] [Related]
11. Curcumin reduces expression of Bcl-2, leading to apoptosis in daunorubicin-insensitive CD34+ acute myeloid leukemia cell lines and primary sorted CD34+ acute myeloid leukemia cells.
Rao J; Xu DR; Zheng FM; Long ZJ; Huang SS; Wu X; Zhou WH; Huang RW; Liu Q
J Transl Med; 2011 May; 9():71. PubMed ID: 21595920
[TBL] [Abstract][Full Text] [Related]
12. Real-time detection and monitoring of the drug resistance of single myeloid leukemia cells by diffused total internal reflection.
Liang L; Jin YX; Zhu XQ; Zhou FL; Yang Y
Lab Chip; 2018 May; 18(10):1422-1429. PubMed ID: 29713720
[TBL] [Abstract][Full Text] [Related]
13. Nanoformulation of EPZ011989 Attenuates EZH2-c-Myb Epigenetic Interaction by Proteasomal Degradation in Acute Myeloid Leukemia.
Kaundal B; Srivastava AK; Dev A; Mohanbhai SJ; Karmakar S; Roy Choudhury S
Mol Pharm; 2020 Feb; 17(2):604-621. PubMed ID: 31904978
[TBL] [Abstract][Full Text] [Related]
14. Discovery of a novel Nrf2 inhibitor that induces apoptosis of human acute myeloid leukemia cells.
Zhang J; Su L; Ye Q; Zhang S; Kung H; Jiang F; Jiang G; Miao J; Zhao B
Oncotarget; 2017 Jan; 8(5):7625-7636. PubMed ID: 28032588
[TBL] [Abstract][Full Text] [Related]
15. Towards an Endpoint Cell Motility Assay by a Microfluidic Platform.
Yeh CF; Tai W; Lin CH; Juang DS; Wu CC; Chen YW; Hsu CH
IEEE Trans Nanobioscience; 2015 Dec; 14(8):835-40. PubMed ID: 26415207
[TBL] [Abstract][Full Text] [Related]
16. Cytotoxic activity to acute myeloid leukemia cells by Antp-TPR hybrid peptide targeting Hsp90.
Horibe T; Kawamoto M; Kohno M; Kawakami K
J Biosci Bioeng; 2012 Jul; 114(1):96-103. PubMed ID: 22425524
[TBL] [Abstract][Full Text] [Related]
17. Biomarkers for RBM39 degradation in acute myeloid leukemia.
Hsiehchen D; Goralski M; Kim J; Xie Y; Nijhawan D
Leukemia; 2020 Jul; 34(7):1924-1928. PubMed ID: 32042080
[No Abstract] [Full Text] [Related]
18. DHA inhibits proliferation and induces ferroptosis of leukemia cells through autophagy dependent degradation of ferritin.
Du J; Wang T; Li Y; Zhou Y; Wang X; Yu X; Ren X; An Y; Wu Y; Sun W; Fan W; Zhu Q; Wang Y; Tong X
Free Radic Biol Med; 2019 Feb; 131():356-369. PubMed ID: 30557609
[TBL] [Abstract][Full Text] [Related]
19. SS30, a novel thioaptamer targeting CD123, inhibits the growth of acute myeloid leukemia cells.
Wang M; Wu H; Duan M; Yang Y; Wang G; Che F; Liu B; He W; Li Q; Zhang L
Life Sci; 2019 Sep; 232():116663. PubMed ID: 31323275
[TBL] [Abstract][Full Text] [Related]
20. Mebendazole exhibits potent anti-leukemia activity on acute myeloid leukemia.
He L; Shi L; Du Z; Huang H; Gong R; Ma L; Chen L; Gao S; Lyu J; Gu H
Exp Cell Res; 2018 Aug; 369(1):61-68. PubMed ID: 29750898
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
